

Serial No.: 09/602,812

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (currently amended) A method of treating cancer in a human, wherein the cancer expresses epidermal growth factor receptor (EGFR) and ErbB2, comprising administering to the human a therapeutically effective amount of an antibody which binds ErbB2 and cross-blocks binding of monoclonal antibody 2C4 (ATCC RH-12697) to ErbB2.
2. (original) The method of claim 1 wherein the antibody blocks ligand activation of an ErbB receptor.
3. (cancelled)
4. (original) The method of claim 1 wherein the cancer is characterized by excessive activation of EGFR.
5. (original) The method of claim 4 wherein the cancer overexpresses an ErbB ligand.
6. (original) The method of claim 5 wherein the ErbB ligand is transforming growth factor alpha (TGF- $\alpha$ ).
7. (original) The method of claim 1 wherein the antibody blocks TGF- $\alpha$  activation of mitogen-activated protein kinase (MAPK).
8. (original) The method of claim 1 wherein the cancer is not characterized by overexpression of ErbB2 receptor.
9. (original) The method of claim 1 wherein the cancer is selected from the group consisting of colon, rectal and colorectal cancer.
- 10.-11. (cancelled)
12. (original) The method of claim 1 wherein the cancer is lung cancer.

Serial No.: 09/602,812

13. (original) The method of claim 12 wherein the cancer is non-small cell lung cancer.

14.-15. (cancelled)

16. (currently amended) The method of claim 1 wherein the antibody has a biological characteristic of monoclonal antibody 2C4 (ATCC HB-12697).

17. (currently amended) The method of claim 16 wherein the antibody comprises a humanized form of monoclonal antibody 2C4 (ATCC HB-12697) ~~or humanized 2C4~~.

18. (original) The method of claim 1 wherein the antibody is an antibody fragment.

19. (original) The method of claim 18 wherein the antibody fragment is a Fab fragment.

20. (original) The method of claim 1 wherein the antibody is not conjugated with a cytotoxic agent.

21. (original) The method of claim 18 wherein the antibody fragment is not conjugated with a cytotoxic agent.

22. (original) The method of claim 1 wherein the antibody is conjugated with a cytotoxic agent.

23. (cancelled)

24. (original) The method of claim 1 comprising administering at least one dose of the antibody to the human in an amount from about 0.5mg/kg to about 10mg/kg.

25. (original) The method of claim 24 comprising administering the dose about every week.

26. (original) The method of claim 24 comprising administering the dose about every three weeks.

Serial No.: 09/602,812

27. (currently amended) A method of treating cancer in a human, wherein the cancer expresses but does not overexpress ErbB2 receptor, comprising administering to the human a therapeutically effective amount of an antibody which binds to ErbB2 and blocks ligand activation of an ErbB receptor substantially more effectively than humanized monoclonal antibody huMAb4D5-8 ~~4D5~~.

28. (original) The method of claim 27 wherein the cancer is breast cancer.

29. (original) The method of claim 28 wherein the cancer is metastatic breast cancer.

30.-33. (cancelled)

34. (currently amended) A method of treating cancer in a human, wherein the cancer is selected from the group consisting of colon, rectal and colorectal cancer which express ErbB2, comprising administering to the human a therapeutically effective amount of an antibody which binds ErbB2 and blocks ligand activation of an ErbB receptor substantially more effectively than humanized monoclonal antibody huMAb4D5-8 ~~4D5~~.

35.-59. (cancelled)

60. (currently amended) A method of treating cancer in a human, wherein the cancer expresses epidermal growth factor receptor (EGFR) and ErbB2, comprising administering to the human a therapeutically effective amount of an antibody which binds ErbB2 and blocks TGF- $\alpha$  activation of mitogen-activated protein kinase (MAPK) substantially more effectively than humanized monoclonal antibody huMAb4D5-8 ~~4D5~~.

61. (currently amended) A method of treating cancer in a human, wherein the cancer expresses epidermal growth factor receptor (EGFR) and ErbB2, comprising administering to the human a therapeutically effective amount of an antibody which has the biological characteristics of ~~monoclonal antibody 2C4~~ of:

(a) blocking HRG activation of an ErbB hetero-oligomer comprising ErbB2 and ErbB3 or ErbB4; and

(b) binding to the ErbB2 epitope bound by monoclonal antibody 2C4 (ATCC HB-12697).

Serial No.: 09/602,812

62. (currently amended) A method of treating cancer in a human, wherein the cancer expresses epidermal growth factor receptor (EGFR) and ErbB2, comprising administering to the human a therapeutically effective amount of a humanized form of monoclonal antibody 2C4 (ATCC HB-12697) or ~~humanized 2C4~~.

63. (currently amended) A method of treating cancer in a human, wherein the cancer expresses epidermal growth factor receptor (EGFR) and ErbB2, comprising administering to the human a therapeutically effective amount of an antibody which binds to the ErbB2 epitope bound by monoclonal antibody 2C4 (ATCC HB-12697).